This product belongs to the macrolide antibiotics, which is the ethyl succinate of erythromycin. It is more stable than erythromycin in gastric acid. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can penetrate the bacterial cell membrane and form a reversible bond with the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

Azithromycin is a 15-membered ring macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. It mainly binds to the 50S subunit of the bacterial ribosome and inhibits RNA-dependent protein synthesis.

Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect and can selectively inhibit fungal sterol synthesis. It is effective against Candida infection, Cryptococcus neoformans infection, Malassezia sacchariflora, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's staining bacteria, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome P-450-dependent enzymes.